Poster Session

(20) The Effect of Selective Serotonin Reuptake Inhibitors on Marginal Bone Levels around Osseointegrated Implants

Co-Author(s)

BB

Basir Barmack, MD, MS, Ed. D

Eastman Institute of Oral Health, University of Rochester, Rochester, NY
Rochester, New York, United States
CG

Catherine Gagnon, DMD

Eastman Institute of Oral Health, University of Rochester, Rochester, NY
Rochester, New York, United States

Lead Author(s)

LJ

Lucy M. Johnson, DDS

Resident, Department of Periodontology
Eastman Institue for Oral Health, University of Rochester, Rochester, NY
PITTSFORD, New York, United States

Co-Author(s)

EK

Elli Anna Kotsailidi, DDS, MS

Eastman Institute of Oral Health, University of Rochester, Rochester, NY
Rochester, New York, United States
AT

Alexandra Tsigarida, DDS, MS

Assοciate Professor and Program Director
University of Rochester - Eastman Institute for Oral Health
Rochester, New York, United States

Introduction: Selective serotonin reuptake inhibitors (SSRIs) are frequently used for the management of anxiety and depression. Evidence shows their negative impact on implant osseointegration, peri-implant health, and implant survival rates. However, there is no evidence of their effect on peri-implant marginal bone levels overtime. The primary goal of this retrospective study is to evaluate the effect of SSRIs on the marginal bone levels of osseointegrated implants.

Methods: Records from patients who received implant placement between 2010 to 2021, were reviewed for this study. Information related to medical history and SSRI use as well as related to the treated site were extracted from patients’ electronic charts. Mesial and distal marginal bone levels were measured relative to the implant platform on radiographs taken at the time of the delivery of the prosthesis and at the most recent follow-up visit. The potential effect of systemic and local factors was assessed.

Results: A total of 152 implants from 105 subjects were included. The mean follow-up period upon implant prosthesis delivery was 46.97 ± 21.87 months. The peri-implant marginal bone loss (MBL) was significantly greater for SSRI users (0.42 0.77 mm) compared to non-SSRI users (0.04 ± 0.65 mm) (MD=0.38 mm, P=0.001, CI [95%] = -0.61 -0.15 mm). Mesial MBL of 0.44 ± 0.85 mm and 0.02 0.70 mm was noted for SSRI-users and non-users, respectively. On the distal aspect, MBL was 0.41 ± 0.94 mm and 0.07 0.73 mm, respectively. Factors such as the type of SSRI, use of proton pump inhibitors, implant location as well as simultaneous bone augmentation with the implant placement, didn’t seem to influence the MBL change within groups or the MBL differences between groups.

Conclusions: The present data suggests that SSRIs are related to greater marginal loss of crestal bone around osseointegrated implants.

Lead Author’s Contributions to the Research Project: The lead author was responsible for data collection, performing the data analysis and the composition of the abstract, in addition to organization and facilitation of the submission